European Commission concludes talks with BioNTech-Pfizer on future COVID-19 vaccine deal

The European Commission has concluded its exploratory talks with BioNTech-Pfizer, the sixth vaccine manufacturer in its portfolio, on purchasing its COVID-19 vaccine candidate.

The contract with BioNTech-Pfizer is expected to include an initial purchase of 200 million doses with an additional 100 million doses optioned if the vaccine is safe and effective. The contract would also include provisions allowing all EU member states to purchase the vaccine, donate vaccines to low- and middle-income countries, or redirect vaccines to other European countries. 
Press release - European Commission